Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil vs. Sufentanil for Sedation in Ventilated ICU Patients
NCT00421720Phase 4Terminated
- Sponsor
- GSK
- Start
- Jan 2007
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of remifentanil in pain and agitation (2 arms), sponsored by GSK. Primary endpoints: Time from initiation of analgesia/sedation to extubation up to 7 days and Time from the start of weaning to extubation up to 7 days. Started Jan 2007; status: terminated.
02
Drugs
remifentanil
03
Conditions
painagitation
Beyond the preview
Go deeper on NCT00421720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00421720.